Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Gross Margin
Transgene Biotek Ltd

99.8%
Current
57%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
99.8%
=
Gross Profit
2m
/
Revenue
2m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
IN
Transgene Biotek Ltd
BSE:526139
525.8m INR
100%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
316.5B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country IN
Market Cap 525.8m INR
Gross Margin
100%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 316.5B USD
Gross Margin
67%
Country US
Market Cap 141.2B USD
Gross Margin
60%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Country US
Market Cap 105.3B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.2B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Transgene Biotek Ltd
Glance View

Market Cap
525.8m INR
Industry
Biotechnology

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

TRABI Intrinsic Value
0.29 INR
Overvaluation 96%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
99.8%
=
Gross Profit
2m
/
Revenue
2m
What is the Gross Margin of Transgene Biotek Ltd?

Based on Transgene Biotek Ltd's most recent financial statements, the company has Gross Margin of 99.8%.